Vaccine Efficacy Articles & Analysis
18 news found
These mouse models can facilitate comprehensive research into the pathogenesis, immune response, and efficacy of antiviral treatments against influenza A infections. Influenza A viruses are members of the Orthomyxoviridae family with a unique genome consisting of eight single-stranded negative-sense RNA fragments. ...
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the launch of its comprehensive portfolio of ELISA Based Assays for vaccine development and bioprocess applications. Vaccine development involves a variety of assays to support vaccine research and development, from early ...
This commitment to excellence in production is vital for the successful deployment of mRNA vaccines on a large scale. mRNA Vaccine Optimization Moreover, Alfa Chemistry recognizes the significance of optimization to enhance the efficacy and stability of mRNA vaccines. ...
Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate efficacy of the company’s single-dose chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. ...
Creative Diagnostics also offers a portfolio of vaccine R&D reagents, including over 40 native antigens of key infectious pathogens, such as Corynebacterium diphtheriae, Clostridium tetani, enterovirus, hepatitis virus, influenza virus, poliovirus, rotavirus, Streptococcus pneumoniae, and Zika virus. These antigens can be used for a variety of applications, from the ...
This CEPI-supported trial will generate additional evidence to inform booster strategies in people previously vaccinated with vaccines distributed through COVAX, including against variants of ...
ByVaxxinit
The analysis found that participants receiving a booster dose saw a significant increase in neutralizing titers, an important predictor of vaccine efficacy. “As the COVID-19 virus continues to evolve, so does our understanding of the efficacy of vaccines and the critical role they play in protecting people from serious ...
A vaccine utilizing the POP BIO technology, EuCorVac-19, is currently in Phase II clinical studies through an ongoing collaboration and licensing arrangement between POP BIO and the Korean vaccine maker Eubiologics, Co. ...
What sets our test apart is that it uses YourBio Health’s innovative blood collection device, that is both convenient and nearly painless.” While COVID-19 vaccines are highly effective, some studies have suggested not all people retain vaccine antibodies for longer than a few weeks or months – potentially leaving them unknowingly at higher ...
Published online in Preprints with The Lancet, this vaccine's high levels of protective efficacy hold promise of becoming an important tool for global malaria eradication. ...
ByNovavax
Speaking on the urgent need for vaccines with increased efficacy, EnGen Bio CEO Dr. Mark Alfenito stated, “Seasonal flu kills more than 25,000 people in the US, and between a quarter and half a million people worldwide, every year. ...
(Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom (U.K.) of NVX–CoV2373, the company's vaccine candidate. ...
ByNovavax
The unique nature and genetic makeup of the influenza virus poses a challenge to researchers focused on influenza treatment and vaccination. To be effective, influenza vaccines must be “matched” to the current, circulating viral strain and administered each year, and even then they have limited effectiveness due to ...
AKCP Coronavirus Vaccine Delivery Monitoring Solution The COVID-19 vaccines coming from Pfizer and Moderna both require storage and transportation at low temperatures. The Pfizer vaccine at -70°C +/- 10°C whereas Moderna requires -20°C. ...
ByAKCP
IMX313 is an antigen re-engineering pro-immunogenic technology which significantly improves the efficacy of vaccines with which it is used. Thanks to IMX313, Imaxio is currently developing a clinical-stage pipeline composed of several vaccine candidates indicated to prevent or treat malaria (phase I), influenza (preclinical phase), and some types ...
Submitted in 2012 and 2013, and respectively entitled “Modified coiled-coil type proteins having improved properties” and “Influenza nucleoprotein vaccines”, these two patents offer additional cover on the American market to the new generation of Imaxio’s antigen re-engineering technology, as well as to its influenza vaccine ...
The aim of the OPTIVAC project is to improve the efficacy of vaccines for seasonal influenza and current pandemics. To achieve this, it will develop a candidate vaccine comprising a recombinant, proprietary, and highly immunogenic version of the influenza virus nucleoprotein (NP). The candidate vaccine from the OPTIVAC project ...
DATELINE -- During the vaccine production process, dissolved and gaseous oxygen measurement is critical to optimize the gas intertization phase. ...